Phase Ib/II Study Of CRLX 101 (Cerulean) In Combination With Bevacizumab In The Treatment Of Patients With Advanced Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

09 Jun 2016 According to a Cerulean Pharma media release, primary endpoint of recommended phase II dose (A primary aim in phase Ib is to determine the recommended phase II camptothecin dose has been met.
04 Nov 2015 According to a Cerulean Pharma media release, results from this study were presented at the 2015 International Kidney Cancer Symposium.
02 Jun 2015 Final results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com